AIM: The aim of this study was to test for the influence of ascorbic acid on tumorigenicity and metastases of implanted PAIII prostate cancer adenocarcinoma cells in syngeneic LW rats. MATERIALS AND METHODS: Hormone-refractory prostate cancer PAIII cells were implanted subcutaneously into immunologically intact, Lobund-Wistar (LW) rats. Intraperitoneal pharmacological doses of ascorbic acid were administered each day for the ensuing 30 days. On the 40th day, animals were sacrificed. Local tumor weights were measured, and metastases were counted. RESULTS: At the end of the 40 day experimental period, the primary tumors were found to be significantly reduced in weight (p=0.026). In addition, sub-pleural lung metastases were even more profoundly reduced in number and size (p=0.009). Grossly enlarged ipsilateral lymph node metastases declined from 7 of 15 rats to 1 of 15 rats. CONCLUSION: Pharmacological doses of ascorbic acid suppress tumor growth and metastases in hormone-refractory prostate cancer.
AIM: The aim of this study was to test for the influence of ascorbic acid on tumorigenicity and metastases of implanted PAIII prostate cancer adenocarcinoma cells in syngeneic LW rats. MATERIALS AND METHODS: Hormone-refractory prostate cancer PAIII cells were implanted subcutaneously into immunologically intact, Lobund-Wistar (LW) rats. Intraperitoneal pharmacological doses of ascorbic acid were administered each day for the ensuing 30 days. On the 40th day, animals were sacrificed. Local tumor weights were measured, and metastases were counted. RESULTS: At the end of the 40 day experimental period, the primary tumors were found to be significantly reduced in weight (p=0.026). In addition, sub-pleural lung metastases were even more profoundly reduced in number and size (p=0.009). Grossly enlarged ipsilateral lymph node metastases declined from 7 of 15 rats to 1 of 15 rats. CONCLUSION: Pharmacological doses of ascorbic acid suppress tumor growth and metastases in hormone-refractory prostate cancer.
Authors: Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan Journal: J Transl Med Date: 2011-03-04 Impact factor: 5.531
Authors: Michael Graham Espey; Ping Chen; Brian Chalmers; Jeanne Drisko; Andrew Y Sun; Mark Levine; Qi Chen Journal: Free Radic Biol Med Date: 2011-03-12 Impact factor: 7.376
Authors: Brianne R O'Leary; Elena K Ruppenkamp; Garett J Steers; Juan Du; Rory S Carroll; Brett A Wagner; Garry R Buettner; Joseph J Cullen Journal: Pancreas Date: 2022-09-13 Impact factor: 3.243
Authors: Brianne R O'Leary; Frederick K Houwen; Chase L Johnson; Bryan G Allen; James J Mezhir; Daniel J Berg; Joseph J Cullen; Douglas R Spitz Journal: Radiat Res Date: 2018-03-16 Impact factor: 2.841
Authors: L John Hoffer; Line Robitaille; Robert Zakarian; David Melnychuk; Petr Kavan; Jason Agulnik; Victor Cohen; David Small; Wilson H Miller Journal: PLoS One Date: 2015-04-07 Impact factor: 3.240